Combination immunotherapy regimens in HCC have generally demonstrated superior response rate and longer duration of response when anti- PD-L1 inhibitor with anti-VEGF antibody or anti-CTLA-4 therapies. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.